Cilengitide in bevacizumab-refractory high-grade glioma: Two case reports and critical review of the literature

Anti-Cancer Drugs

Volumn 23, Issue 7, 2012, Pages 749-753

  Lombardi, Giuseppe ^a   Zustovich, Fable ^a   Farina, Patrizia ^a   Polo, Valentina ^a   Farina, Miriam ^a   Puppa, Alessandro Della ^b   Bertorelle, Roberta ^a   Gardiman, Marina Paola ^b   Berti, Franco ^a   Zagonel, Vittorina ^a  

^a VENETO INSTITUTE OF ONCOLOGY IOV IRCCS   (Italy)

^b UNIVERSITY OF PADOVA   (Italy)

Author keywords

angiogenesis; bevacizumab; cilengitide; high grade glioma; recurrent glioma

Indexed keywords

BEVACIZUMAB; CILENGITIDE; GADOLINIUM; IRINOTECAN; ISOCITRATE DEHYDROGENASE 1; ISOCITRATE DEHYDROGENASE 2; METHYLATED DNA PROTEIN CYSTEINE METHYLTRANSFERASE; TEMOZOLOMIDE;

ADULT; CANCER GROWTH; CANCER RECURRENCE; CANCER SURGERY; CASE REPORT; CLINICAL EXAMINATION; CODON; CONTRAST ENHANCEMENT; DEATH; DRUG ACTIVITY; DRUG SAFETY; FEMALE; GENE MUTATION; GLIOBLASTOMA; HUMAN; INFORMED CONSENT; MALE; MULTIPLE CYCLE TREATMENT; NUCLEAR MAGNETIC RESONANCE IMAGING; PHYSICAL EXAMINATION; PRIORITY JOURNAL; PROMOTER REGION; RADIATION DOSE; REVIEW; WILD TYPE;

ADULT; ANGIOGENESIS INHIBITORS; ASTROCYTOMA; BRAIN NEOPLASMS; FEMALE; GLIOMA; HUMANS; INTEGRIN ALPHAVBETA3; MALE; MIDDLE AGED; PLATELET MEMBRANE GLYCOPROTEINS; SALVAGE THERAPY; SNAKE VENOMS;

EID: 84863563759     PISSN: 09594973     EISSN: 14735741     Source Type: Journal    
DOI: 10.1097/CAD.0b013e3283520e2c     Document Type: Review

References (21)

1. Takano S. Glioblastoma angiogenesis: vegf resistance solutions and new strategies based on molecular mechanisms of tumor vessel formation. Brain Tumor Pathol 2012 [Epub ahead of print].
2. Reardon DA, Herndon JE II, Peters K, Desjardins A, Coan A, Lou E, et al. Outcome after bevacizumab clinical trial therapy among recurrent grade III malignant glioma patients. J Neurooncol 2012; 107:213-221.
3. Reardon DA, Desjardins A, Peters KB, Vredenburgh JJ, Gururangan S, Sampson JH, et al. Phase 2 study of carboplatin, irinotecan, and bevacizumab for recurrent glioblastoma after progression on bevacizumab therapy. Cancer 2011; 117:5351-5358.
4. Desgrosellier JS, Cheresh DA. Integrins in cancer: Biological implications and therapeutic opportunities. Nat Rev Cancer 2010; 10:9-22.
5. Tabatabai G, Weller M, Nabors B, Picard M, Reardon D, Mikkelsen T, et al. Targeting integrins in malignant glioma. Target Oncol 2010; 5:175-181.
6. Macdonald DR, Cascino TL, Schold SC Jr, Cairncross JG. Response criteria for phase II studies of supratentorial malignant glioma. J Clin Oncol 1990; 8:1277-1280. (Pubitemid 20195640)
7. Wen PY, Macdonald DR, Reardon DA, Cloughesy TF, Sorensen AG, Galanis E, et al. Updated response assessment criteria for high-Grade gliomas: Response assessment in neuro-Oncology working group. J Clin Oncol 2010; 28:1963-1972.
8. Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJ, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 2005; 352:987-996. (Pubitemid 40349501)
9. Abdollahi A, Folkman J. Evading tumor evasion: Current concepts and perspectives of anti-Angiogenic cancer therapy. Drug Resist Updat 2010; 13:16-28.
10. Byzova TV, Goldman CK, Pampori N, Thomas KA, Bett A, Shattil SJ, et al. A mechanism for modulation of cellular responses to VEGF: Activation of the integrins. Mol Cell 2000; 6:851-860.
11. Nabors LB, Mikkelsen T, Rosenfeld SS, Hochberg F, Akella NS, Fisher JD, et al. Phase I and correlative biology study of cilengitide in patients with recurrent malignant glioma. J Clin Oncol 2007; 25:1651-1657. (Pubitemid 46797943)
12. Reardon DA, Fink KL, Mikkelsen T, Cloughesy TF, O'Neill A, Plotkin S, et al. Randomized phase II study of cilengitide, an integrin-Targeting arginine-Glycine-Aspartic acid peptide, in recurrent glioblastoma multiforme. J Clin Oncol 2008; 26:5610-5617.
13. Stupp R, Hegi ME, Neyns B, Goldbrunner R, Schlegel U, Clement PM, et al. Phase I/IIa study of cilengitide and temozolomide with concomitant radiotherapy followed by cilengitide and temozolomide maintenance therapy in patients with newly diagnosed glioblastoma. J Clin Oncol 2010; 28:2712-2718.
14. Gilbert MR, Kuhn J, Lamborn KR, Lieberman F, Wen PY, Mehta M, et al. Cilengitide in patients with recurrent glioblastoma: The results of NABTC 03-02, a phase II trial with measures of treatment delivery. J Neurooncol 2012; 106:147-153.
15. Riemenschneider MJ, Hegi ME, Reifenberger G. MGMT promoter methylation in malignant gliomas. Target Oncol 2010; 5:161-165.
16. Sadones J, Michotte A, Veld P, Chaskis C, Sciot R, Menten J, et al. MGMT promoter hypermethylation correlates with a survival benefit from temozolomide in patients with recurrent anaplastic astrocytoma but not glioblastoma. Eur J Cancer 2009; 45:146-153.
17. Yan H, Parsons DW, Jin G, McLendon R, Rasheed BA, Yuan W, et al. IDH1 and IDH2 mutations in gliomas. N Engl J Med 2009; 360:765-773.
18. Kloosterhof NK, Bralten LB, Dubbink HJ, French PJ, van den Bent MJ. Isocitrate dehydrogenase-1 mutations: A fundamentally new understanding of diffuse glioma? Lancet Oncol 2010; 12:83-91.
19. Zhao S, Lin Y, Xu W, Jiang W, Zha Z, Wang P, et al. Glioma-Derived mutations in IDH1 dominantly inhibit IDH1 catalytic activity and induce HIF-1alpha. Science 2009; 324:261-265.
20. Reynolds AR, Hart IR,Watson AR,Welti JC, Silva RG, Robinson SD, et al. Stimulation of tumor growth and angiogenesis by low concentrations of RGD-Mimetic integrin inhibitors. Nat Med 2009; 15: 392-400.
21. Goldlust SA, Cavaliere R, Newton HB, Hsu M, Deangelis LM, Batchelor TT, et al. Bevacizumab for glioblastoma refractory to vascular endothelial growth factor receptor inhibitors. J Neurooncol 2011 [Epub ahead of print].